This is a Phase II, Open-label, Multi-Dose Study of the Monoclonal Antibody MDX-1097 to determine the efficacy of the antibody in patients who have received prior treatment for myeloma and have kappa light chain restricted multiple myeloma with stable measurable disease.
An Open-label Phase I Study of the Safety and Efficacy of MDX-1097, an human IgG1k chimeric monoclonal antibody, in the Treatment of Previously Treated Kappa Light Chain Restricted Multiple Myeloma Patients with Stable Measurable Disease to determine the Safety, Tolerability and Maximum Tolerated Dose
100 项与 Immune System Therapeutics Ltd. 相关的临床结果
0 项与 Immune System Therapeutics Ltd. 相关的专利(医药)
100 项与 Immune System Therapeutics Ltd. 相关的药物交易
100 项与 Immune System Therapeutics Ltd. 相关的转化医学